A new responsive material ‘glued’ together with short strands of DNA, and capable of translating thermal and chemical signals into visible physical changes, could underpin a new class of biosensors or drug delivery systems.
Innovation is about the application of new ideas, discoveries and inventions. The innovative and entrepreneurial spirit of the members of the University of Cambridge is enshrined in the University’s mission statement to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. The foundation for innovation is the steady supply of excellent ideas, of which there is an abundance at Cambridge. Ingenuity and creativity, alongside the fundamental research which underpins these ideas and combined with the constant exchange of ideas between academics and companies, governments and NGOs has been the recipe for this success.
Various mechanisms are in place to help our academics nurture future innovation. As well as dedicated departmental support structures, Cambridge Enterprise provides technology transfer, consultancy services and seed fund opportunities, and the Centre for Entrepreneurial Learning (CfEL) within the Judge Business School provides networking opportunities with peers. In addition, Cambridge-based initiatives physically embedded within the University such as ideaSpace provide hubs for entrepreneurs to develop ideas.
A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has today become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.
The University is a partner in a three-year, multi-million pound project which will test public reaction to driverless cars, and conduct real-world testing on public roads around Milton Keynes and Coventry.